Skip to main content
Top
Published in: EJNMMI Research 1/2017

Open Access 01-12-2017 | Original research

A human PET study of [11C]HMS011, a potential radioligand for AMPA receptors

Authors: Keisuke Takahata, Yasuyuki Kimura, Chie Seki, Masaki Tokunaga, Masanori Ichise, Kazunori Kawamura, Maiko Ono, Soichiro Kitamura, Manabu Kubota, Sho Moriguchi, Tatsuya Ishii, Yuhei Takado, Fumitoshi Niwa, Hironobu Endo, Tomohisa Nagashima, Yoko Ikoma, Ming-Rong Zhang, Tetsuya Suhara, Makoto Higuchi

Published in: EJNMMI Research | Issue 1/2017

Login to get access

Abstract

Background

α-Amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor is a primary mediator of fast glutamatergic excitatory signaling in the brain and has been implicated in diverse neuropsychiatric diseases. We recently developed a novel positron emission tomography (PET) ligand, 2-(1-(3-([11C]methylamino)phenyl)-2-oxo-5-(pyrimidin-2-yl)-1,2-dihydropyridin-3-yl) benzonitrile ([11C]HMS011). This compound is a radiolabelled derivative of perampanel, an antiepileptic drug acting on AMPA receptors, and was demonstrated to have promising in vivo properties in the rat and monkey brains. In the current study, we performed a human PET study using [11C]HMS011 to evaluate its safety and kinetics.
Four healthy male subjects underwent a 120-min PET scan after injection of [11C]HMS011. Arterial blood sampling and metabolite analysis were performed to obtain parent input functions for three of the subjects using high-performance liquid chromatography. Regional distribution volumes (V Ts) were calculated based on kinetic models with and without considering radiometabolite in the brain. The binding was also quantified using a reference tissue model with white matter as reference.

Results

Brain uptake of [11C]HMS011 was observed quickly after the injection, followed by a rapid clearance. Three hydrophilic and one lipophilic radiometabolites appeared in the plasma, with notable individual variability. The kinetics in the brain with apparent radioactivity retention suggested that the lipophilic radiometabolite could enter the brain. A dual-input graphical model, an analytical model designed in consideration of a radiometabolite entering the brain, well described the kinetics of [11C]HMS011. A reference tissue model showed small radioligand binding potential (BP*ND) values in the cortical regions (BP*ND = 0–0.15). These data suggested specific binding component of [11C]HMS011 in the brain.

Conclusions

Kinetic analyses support some specific binding of [11C]HMS011 in the human cortex. However, this ligand may not be suitable for practical AMPA receptor PET imaging due to the small dynamic range and metabolite in the brain.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jane DE, Lodge D, Collingridge GL. Kainate receptors: pharmacology, function and therapeutic potential. Neuropharmacology. 2009;56:90–113.CrossRefPubMed Jane DE, Lodge D, Collingridge GL. Kainate receptors: pharmacology, function and therapeutic potential. Neuropharmacology. 2009;56:90–113.CrossRefPubMed
2.
go back to reference Hwa GG, Avoli M, Oliver A, Villemure JG. Bicuculline-induced epileptogenesis in the human neocortex maintained in vitro. Exp Brain Res. 1991;83:329–39.CrossRefPubMed Hwa GG, Avoli M, Oliver A, Villemure JG. Bicuculline-induced epileptogenesis in the human neocortex maintained in vitro. Exp Brain Res. 1991;83:329–39.CrossRefPubMed
3.
go back to reference Carriedo SG, Yin HZ, Weiss JH. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci. 1996;16:4069–79.PubMed Carriedo SG, Yin HZ, Weiss JH. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci. 1996;16:4069–79.PubMed
4.
go back to reference Alt A, Nisenbaum ES, Bleakman D, Witkin JM. A role for AMPA receptors in mood disorders. Biochem Pharmacol. 2006;71:1273–88.CrossRefPubMed Alt A, Nisenbaum ES, Bleakman D, Witkin JM. A role for AMPA receptors in mood disorders. Biochem Pharmacol. 2006;71:1273–88.CrossRefPubMed
5.
go back to reference Noga JT, Wang H. Further postmortem autoradiographic studies of AMPA receptor binding in schizophrenia. Synapse. 2002;45:250–8.CrossRefPubMed Noga JT, Wang H. Further postmortem autoradiographic studies of AMPA receptor binding in schizophrenia. Synapse. 2002;45:250–8.CrossRefPubMed
6.
go back to reference Yamaguchi S, Donevan SD, Rogawski MA. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 1993;15:179–84.CrossRefPubMed Yamaguchi S, Donevan SD, Rogawski MA. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 1993;15:179–84.CrossRefPubMed
8.
go back to reference Hibi S, Ueno K, Nagato S, Kawano K, Ito K, Norimine Y, et al. Discovery of 2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (Perampanel): a novel, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist. J Med Chem. 2012;55:10584–600.CrossRefPubMed Hibi S, Ueno K, Nagato S, Kawano K, Ito K, Norimine Y, et al. Discovery of 2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (Perampanel): a novel, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist. J Med Chem. 2012;55:10584–600.CrossRefPubMed
9.
go back to reference Hsu WWQ, Sing CW, He Y, Worsley AJ, Wong ICK, Chan EW. Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy. CNS Drugs. 2013;27:817–27.CrossRefPubMedPubMedCentral Hsu WWQ, Sing CW, He Y, Worsley AJ, Wong ICK, Chan EW. Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy. CNS Drugs. 2013;27:817–27.CrossRefPubMedPubMedCentral
10.
go back to reference Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Squillacote D, et al. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia. 2013;54:126–34.CrossRefPubMed Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Squillacote D, et al. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia. 2013;54:126–34.CrossRefPubMed
11.
go back to reference Oi N, Tokunaga M, Suzuki M, Nagai Y, Nakatani Y, Yamamoto N, et al. Development of novel PET probes for central 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid receptors. J Med Chem. 2015;58:8444–62.CrossRefPubMed Oi N, Tokunaga M, Suzuki M, Nagai Y, Nakatani Y, Yamamoto N, et al. Development of novel PET probes for central 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid receptors. J Med Chem. 2015;58:8444–62.CrossRefPubMed
12.
go back to reference Rainbow TC, Wieczorek CM, Halpain S. Quantitative autoradiography of binding sites for [3H] AMPA, a structural analogue of glutamic acid. Brain Res. 1984;309:173–7.CrossRefPubMed Rainbow TC, Wieczorek CM, Halpain S. Quantitative autoradiography of binding sites for [3H] AMPA, a structural analogue of glutamic acid. Brain Res. 1984;309:173–7.CrossRefPubMed
13.
go back to reference Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716–23.CrossRef Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716–23.CrossRef
14.
go back to reference Fujita M, Seibyl JP, Verhoeff NP, Ichise M, Baldwin RM, Zoghbi SS, et al. Kinetic and equilibrium analyses of [123I]epidepride binding to striatal and extrastriatal dopamine D2 receptors. Synapse. 1999;34:290–304.CrossRefPubMed Fujita M, Seibyl JP, Verhoeff NP, Ichise M, Baldwin RM, Zoghbi SS, et al. Kinetic and equilibrium analyses of [123I]epidepride binding to striatal and extrastriatal dopamine D2 receptors. Synapse. 1999;34:290–304.CrossRefPubMed
15.
go back to reference Hawkins RA, Phelps ME, Huang S-C. Effects of temporal sampling, glucose metabolic rates, and disruptions of the blood-brain barrier on the FDG model with and without a vascular compartment: studies in human brain tumors with PET. J Cereb Blood Flow Metab. 1986;6:170–83.CrossRefPubMed Hawkins RA, Phelps ME, Huang S-C. Effects of temporal sampling, glucose metabolic rates, and disruptions of the blood-brain barrier on the FDG model with and without a vascular compartment: studies in human brain tumors with PET. J Cereb Blood Flow Metab. 1986;6:170–83.CrossRefPubMed
16.
go back to reference Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time—activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740–7.CrossRefPubMed Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time—activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740–7.CrossRefPubMed
17.
go back to reference Ichise M, Fujita M, Seibyl JP, Verhoeff NP, Baldwin RM, Zoghbi SS, et al. Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]epidepride SPECT. J Nucl Med. 1999;40:1902–12.PubMed Ichise M, Fujita M, Seibyl JP, Verhoeff NP, Baldwin RM, Zoghbi SS, et al. Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]epidepride SPECT. J Nucl Med. 1999;40:1902–12.PubMed
18.
go back to reference Ichise M, Ballinger JR, Golan H, Vines D, Luong A, Tsai S, et al. Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J Nucl Med. 1996;37:513–20.PubMed Ichise M, Ballinger JR, Golan H, Vines D, Luong A, Tsai S, et al. Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J Nucl Med. 1996;37:513–20.PubMed
19.
go back to reference Weaver DR. A2a adenosine receptor gene expression in developing rat brain. Brain Res Mol Brain Res. 1993;20:313–27.CrossRefPubMed Weaver DR. A2a adenosine receptor gene expression in developing rat brain. Brain Res Mol Brain Res. 1993;20:313–27.CrossRefPubMed
20.
go back to reference Peterfreund RA, MacCollin M, Gusella J, Fink JS. Characterization and expression of the human A2a adenosine receptor gene. J Neurochem. 1996;66:362–8.CrossRefPubMed Peterfreund RA, MacCollin M, Gusella J, Fink JS. Characterization and expression of the human A2a adenosine receptor gene. J Neurochem. 1996;66:362–8.CrossRefPubMed
Metadata
Title
A human PET study of [11C]HMS011, a potential radioligand for AMPA receptors
Authors
Keisuke Takahata
Yasuyuki Kimura
Chie Seki
Masaki Tokunaga
Masanori Ichise
Kazunori Kawamura
Maiko Ono
Soichiro Kitamura
Manabu Kubota
Sho Moriguchi
Tatsuya Ishii
Yuhei Takado
Fumitoshi Niwa
Hironobu Endo
Tomohisa Nagashima
Yoko Ikoma
Ming-Rong Zhang
Tetsuya Suhara
Makoto Higuchi
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2017
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-017-0313-0

Other articles of this Issue 1/2017

EJNMMI Research 1/2017 Go to the issue